{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T03:03:10Z","timestamp":1789354990731,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Immunotherapy\u2010associated intestinal tract injury is increasingly recognized; however, histological patterns associated with specific agents remain incompletely defined. Data directly comparing CD19\u2010 and BCMA\u2010directed CAR T therapies with other B\u2010cell\u2010targeted treatments are limited, and histological findings associated with teclistamab in the gastrointestinal tract have not been well described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed intestinal biopsies from patients treated with BCMA\u2010directed CAR T (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), teclistamab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), CD19\u2010directed CAR T (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931) and rituximab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911), identifying distinct but overlapping histological patterns. Lamina propria plasma cell depletion was the most prominent finding in BCMA\u2010targeted therapies (74% BCMA CAR T, 88% teclistamab), occurring at significantly lower rates in CD19 CAR T (32%) and rituximab (27%) cohorts (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Crypt apoptotic bodies (65% BCMA CAR T, 88% teclistamab, 48% CD19 CAR T, 45% rituximab) and active inflammation (48% BCMA CAR T, 38% teclistamab, 35% CD19 CAR T, 9% rituximab) were also observed. Intraepithelial lymphocytosis, villous blunting, goblet cell depletion and erosion were infrequent. No significant histopathological differences were identified between agents sharing a similar target.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intestinal biopsies from patients treated with plasma cell and B\u2010cell\u2010targeted immunotherapies showed distinct but overlapping histological patterns. Lamina propria plasma cell depletion was most prominent in BCMA\u2010directed therapies, while crypt apoptotic bodies and active inflammation were identified across all treatment groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/his.70277","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:22:19Z","timestamp":1789352539000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of intestinal histopathological changes\u00a0following teclistamab,\n                    <scp>BCMA<\/scp>\n                    \u2010directed\n                    <scp>CAR<\/scp>\n                    T,\n                    <scp>CD19<\/scp>\n                    \u2010directed\n                    <scp>CAR<\/scp>\n                    T and rituximab therapies"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2264-493X","authenticated-orcid":false,"given":"Olivia J","family":"Leung","sequence":"first","affiliation":[{"name":"Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-4109","authenticated-orcid":false,"given":"Esther","family":"Baranov","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2426-8552","authenticated-orcid":false,"given":"Isairis Peralta","family":"Valerio","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Collingwood","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Respond","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-2251","authenticated-orcid":false,"given":"Don","family":"Siegel","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania  Philadelphia Pennsylvania USA"},{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Devi","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-8122","authenticated-orcid":false,"given":"Kristen M.","family":"Stashek","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B\u2010cell hematologic malignancies: A review of 20\u2009years of clinical experience","volume":"34","author":"Salles G","year":"2017","journal-title":"Adv. Ther."},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June CH","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B\u2010cell maturation antigen\u2009\u00d7\u2009CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC\u20101): A multicentre, open\u2010label, single\u2010arm, phase 1 study","volume":"398","author":"Usmani SZ","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13717","article-title":"Teclistamab: Mechanism of action, clinical, and translational science","volume":"17","author":"Guo Y","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of Extramedullary myeloma with Talquetamab and Teclistamab","volume":"394","author":"Kumar S","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: Importance of immunoglobulin supplementation","volume":"8","author":"Frerichs KA","year":"2024","journal-title":"Blood Adv."},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T\u00a0cells and T\u2010cell therapies for cancer: A translational science review","volume":"332","author":"Brudno JN","year":"2024","journal-title":"JAMA"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith R","year":"2023","journal-title":"J. Transl. Med."},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/COC.0000000000000596","article-title":"Gastrointestinal adverse events observed after chimeric antigen receptor T\u2010cell therapy","volume":"42","author":"Abu\u2010Sbeih H","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41417-024-00752-0","article-title":"Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T\u2010cell recipients: A real\u2010world study","volume":"31","author":"Song Z","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e19505","article-title":"Risk of gastrointestinal adverse events associated with chimeric antigen receptor T\u2010cell therapy (CAR\u2010T): A nationwide analysis","volume":"42","author":"Khan S","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell\u2010associated enterocolitis following chimeric antigen receptor T\u2010cell therapy in multiple myeloma","volume":"14","author":"Fortuna GG","year":"2024","journal-title":"Blood Cancer J."},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/ibd\/izaa320","article-title":"Colitis after CAR T\u2010cell therapy for refractory large B\u2010cell lymphoma responds to anti\u2010integrin therapy","volume":"27","author":"Hashim A","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105791","article-title":"Chimeric antigen receptor (CAR) T\u2010cell therapy\u2010related gastrointestinal toxicity: Histologic features and morphologic mimics","volume":"158","author":"Karimi SS","year":"2025","journal-title":"Hum. Pathol."},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/PAS.0000000000002499","article-title":"Patterns of gastrointestinal injury associated with CAR\u2010T therapy for patients with multiple myeloma","volume":"50","author":"Osnis L","year":"2026","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2026.100991","article-title":"Multiple myeloma and mimicry: Gastrointestinal tract histologic findings in patients following chimeric antigen receptor T\u2010cell therapy and anti\u2010Cd38 monoclonal antibodies","volume":"39","author":"Requena DO","year":"2026","journal-title":"Mod. Pathol."},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/PAS.0000000000002544","article-title":"Histopathologic features of chimeric antigen receptor (CAR) T\u2010cell therapy\u2010associated gastrointestinal mucosal injury: A case series and review of literature","volume":"50","author":"Baroudi I","year":"2026","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/COC.0000000000000553","article-title":"Clinical features of rituximab\u2010associated gastrointestinal toxicities","volume":"42","author":"Mallepally N","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100770","article-title":"The histologic Spectrum of rituximab\u2010associated common variable immunodeficiency\u2010like enteropathy","volume":"38","author":"Jafari P","year":"2025","journal-title":"Mod. Pathol."},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ajcp\/aqab133","article-title":"Histologic findings and tissue B\u2010cell depletion in endoscopic mucosal biopsy specimens of the gastrointestinal tract after treatment with rituximab","volume":"157","author":"Kmeid M","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.seminhematol.2025.12.004","article-title":"BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape","volume":"62","author":"Sezer E","year":"2025","journal-title":"Semin. Hematol."},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41591-025-04121-8","article-title":"CD4+ T\u00a0cells mediate CAR\u2010T cell\u2010associated immune\u2010related adverse events after BCMA CAR\u2010T cell therapy","volume":"32","author":"Ho M","year":"2026","journal-title":"Nat. Med."},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02768","article-title":"Plasma cells, the next generation: Beyond antibody secretion","volume":"10","author":"Pioli PD","year":"2019","journal-title":"Front. Immunol."},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41575-023-00755-6","article-title":"Human intestinal B cells in inflammatory diseases","volume":"20","author":"Spencer J","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long\u2010lived plasma cells and humoral immunity in individuals responding to CD19\u2010directed CAR T\u2010cell therapy","volume":"128","author":"Bhoj VG","year":"2016","journal-title":"Blood"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude SL","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_2_12_28_1","article-title":"Gastrointestinal (GI) pathology findings in patients receiving bispecific T\u2010cell engagers (BiTEs)","volume":"106","author":"Nguyen H","year":"2026","journal-title":"Lab Invest"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ibd\/izz049","article-title":"Intestinal CD103+ CD4+ and CD103+ CD8+ T\u2010cell subsets in the gut of inflammatory bowel disease patients at diagnosis and during follow\u2010up","volume":"25","author":"Roosenboom B","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41385-020-0315-5","article-title":"CD4+ T\u00a0cells persist for years in the human small intestine and display a TH1 cytokine profile","volume":"14","author":"Bartolom\u00e9\u2010Casado R","year":"2021","journal-title":"Mucosal Immunol."},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T\u2010cell lymphoma after Cilta\u2010cel CAR T\u2010cell therapy","volume":"390","author":"Ozdemirli M","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025032347","article-title":"Ruxolitinib for Ciltacabtagene Autoleucel\u2010associated refractory diarrhea","volume":"147","author":"Blumenberg V","year":"2026","journal-title":"Blood J."},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/modpathol.2010.163","article-title":"Gastrointestinal pathology of autologous graft\u2010versus\u2010host disease following hematopoietic stem cell transplantation: A clinicopathological study of 17 cases","volume":"24","author":"Cogbill CH","year":"2011","journal-title":"Mod. Pathol."},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/PAS.0b013e3180cab60c","article-title":"Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): A Clinicopathologic study and review","volume":"31","author":"Daniels JA","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/00000478-199610000-00010","article-title":"Gastrointestinal pathology in patients with common variable immunodeficiency and X\u2010linked agammaglobulinemia","volume":"20","author":"Washington K","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/PAS.0000000000000317","article-title":"Gastrointestinal biopsy findings of autoimmune enteropathy: A review of 25 cases","volume":"38","author":"Masia R","year":"2014","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/his.70277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:22:23Z","timestamp":1789352543000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.70277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":36,"alternative-id":["10.1111\/his.70277"],"URL":"https:\/\/doi.org\/10.1111\/his.70277","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"assertion":[{"value":"2026-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"his.70277"}}